---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-022337"
form_type: "8-K"
ticker: null
cik: "0000799698"
company_name: "LadRx Corp"
filed_at: "2023-06-26T23:59:59+00:00"
generated_at: "2026-06-13T17:24:56.866712+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# LadRx sells aldoxorubicin and arimoclomol royalty rights to XOMA for $5M upfront; up to $6M more

## Summary
- Gross proceeds $5M at closing; potential $6M milestones: $1M on FDA acceptance of arimoclomol NDA, $1M on first sale, $4M on aldoxorubicin FDA approval.
- XOMA acquires all milestone and royalty payments from ImmunityBio and Zevra, net of existing obligations.
- Proceeds to advance lead candidate LADR-7 toward IND filing; 12 months of final IND-enabling work estimated.
- Transaction structured as non-dilutive financing; Roth Capital Partners acted as placement agent.

## SEC filing metadata
- accession: 0001493152-23-022337
- form_type: 8-K
- cik: 0000799698
- company_name: LadRx Corp
- filed_at: 2023-06-26T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 2.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/799698/000149315223022337/0001493152-23-022337-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/799698/000149315223022337/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-022337
- JSON: https://secwatch.observer/filing/0001493152-23-022337.json
- Plain text: https://secwatch.observer/filing/0001493152-23-022337.txt

## Key facts
- M&A Transactions
  LadRx Corp completed a disposition involving XOMA (US) LLC for $5 million (closed 2023-06-21).
  - Action: disposition
  - Counterparty: XOMA (US) LLC
  - Consideration: $5 million
  - Closing: 2023-06-21
  source text: purchase price paid to the Company for the sale, transfer, assignment and conveyance of the Company’s right, title and interest in and to aldoxorubicin and arimoclomol was $5 million, less certain transaction fees and expenses. As previously reported, on July 27, 2017, the Company entered into an exclusive worldwide license agreement (as amended, the “
  evidence_url: https://www.sec.gov/Archives/edgar/data/799698/000149315223022337/0001493152-23-022337-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.